.Attribute Medication, Published online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in strengthened progression-free as well as total survival, resulting in FDA approval and a brand new procedure choice for patients.